蚓激酶单用与联合小剂量尿激酶治疗急性进展性脑梗死对比观察

Comparative Observation on Lumbrokinase Monotherapy or Combination with Low Dose of Urokinase in Treatment of Acute Progressive Cerebral Infarction

目的:探究蚓激酶单用与联合小剂量尿激酶治疗急性进展性脑梗死的临床疗效。方法:选择2015年6月-2016年8月本院收治的发病24 h后病情仍加重的颈内动脉系统急性进展性脑梗死患者60例,根据随机数字表法分为两组,每组30例。对照组给予口服蚓激酶治疗,研究组给予蚓激酶联合尿激酶治疗。比较两组神经功能缺损程度、日常生活活动能力、临床疗效及不良反应发生情况。结果:治疗后,对照组NIHSS评分为(11.36±5.42)分,研究组为(8.74±3.11)分,组间比较差异有统计学意义(P<0.05);对照组治疗后ADL评分为(51.85±13.12)分,研究组为(59.62±14.95)分,组间比较差异有统计学意义(P<0.05);对照组治疗有效率为73.33%(22/30),研究组93.33%(28/30),组间比较差异有统计学意义(P<0.05);治疗期间,对照组不良反应发生率为16.67%(5/30),研究组为10.00%(3/30),组间比较差异无统计学意义(P>0.05)。结论:与单用蚓激酶相比,对急性进展性脑梗死患者实施蚓激酶联合小剂量尿激酶治疗效果更优,能有效改善患者神经功能和日常生活活动能力,提高临床疗效,不会增加毒副反应,安全性高,值得临床应用与推广。

Objective： To investigate the clinical efficacy of Lumbrokinase Monotherapy or combination with low dose of Urokinase in treatment of acute progressive cerebral infarction （ APCI ） .Method： 60 patients with internal carotid artery system of APCI still aggravated after onset for 24 h in our hospital from June 2015 to August 2016 were selected, and they were divided into two groups by random number table, 30 cases in each group. The control group orally took Lumbrokinase monotherapy, the research group took Lumbrokinase combined with Urokinase.The neurological deficit degree, activities of daily living （ ADL ）, clinical efficacy and adverse reactions of two groups were compared.Result： After treatment, NIHSS score of the control group was （ 11.36 ± 5.42 ） points, and the research group was （ 8.74± 3.11 ） points, there was statistical difference （ P〈0.05 ） .After treatment, ADL score of the control group was （ 51.85 ± 13.12 ） points, and the research group was （ 59.62 ± 14.95 ） points, there was statistical difference （P〈0.05） .The effective rate of the control group was 73.33% （22/30）, and the research group was 93.33% （ 28/30 ）, there was statistical difference （ P〈0.05 ） .During treatment, the incidence of adverse reactions of the control group was 16.67% （ 5/30 ）, and the research group was 10.00% （ 3/30 ）, there was no statistical difference （ P〉0.05 ） .Conclusion： Compared with Lumbrokinase monotherapy, Lumbrokinase combined with low dose of Urokinase for APCI patients has better curative effects, it can effectively improve nerve function and ADL, increase clinical efficacy, has high safety and not add toxic-side response, which is worthy of clinical application and promotion.